Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Cash from Financing Activities over the past 3 years, most recently at $59.1 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $59.1 million for Q4 2025, down 30.55% from a year ago — trailing twelve months through Dec 2025 was $214.5 million (up 59.06% YoY), and the annual figure for FY2025 was $214.5 million, up 59.06%.
  • Cash from Financing Activities for Q4 2025 was $59.1 million at Tonix Pharmaceuticals Holding, down from $94.9 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TNXP hit a ceiling of $94.9 million in Q3 2025 and a floor of -$11.5 million in Q1 2023.
  • Median Cash from Financing Activities over the past 3 years was $25.9 million (2023), compared with a mean of $32.2 million.
  • Peak annual rise in Cash from Financing Activities hit 23464.62% in 2025, while the deepest fall reached 30.55% in 2025.
  • Tonix Pharmaceuticals Holding's Cash from Financing Activities stood at $40.7 million in 2023, then surged by 109.15% to $85.2 million in 2024, then tumbled by 30.55% to $59.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were $59.1 million (Q4 2025), $94.9 million (Q3 2025), and $11.0 million (Q2 2025) per Business Quant data.